Resumo

CATANO CORREA, JUAN CARLOS  e  SENIOR SANCHEZ, JUAN MANUEL. ANTITHROMBOTIC THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION. Iatreia [online]. 2003, vol.16, n.2, pp.153-162. ISSN 0121-0793.

THE NUMBER OF PEOPLE WITH ATRIAL FIBRILLATION (AF) in the United States has been projected to increase from the current 2.2 million to 3 million in 2020. It is characterized by the presence of rapid and irregular waves on the base line that vary in size, shape and timing. It is particularly frequent in the elderly. In AF multiple, small microreentrant circuits are constantly arising in the atria, colliding, being extinguished, and arising again; a critical mass of atrial tissue is required to sustain the minimal number of simultaneous circuits necessary for the perpetuation of the arrhythmia. Two recent studies permit to conclude that the rhythm control strategy offers no survival advantage over the rate control strategy, and there are potential advantages, such as the lower risk of adverse drug effects, with the rate control strategy. One of the most severe complications of AF are the thromboembolic events mainly to the central nervous system. AF is an important independent risk factor for the embolic stroke, responsible for as many as 15% of strokes and for 30% in the group 80 to 89 years old. We analyzed different primary and secondary prevention studies in patients with non-valvular FA, which support the recommendations of guidelines developed by the American College of Cardiology, the American Heart Association, the European Society of Cardiology and ACCP.

Palavras-chave : ANTIAGREGACIÓN; ANTICOAGULACIÓN; EVENTOS TROMBOEMBÓLICOS; FIBRILACIÓN AURICULAR; TERAPIA ANTITROMBÓTICA.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )